599 / 1082
S583
ESTRO 36 2017
_______________________________________________________________________________________________
radiotherapy arm were not inferior results.
Therefore definitive radiotherapy may be considered
alternative treatment modality in patients with
inoperable adenoid cystic carcinoma of head and neck.
EP-1068 Hypoxic imaging obtained at 2-h
postinjection in FMISO-PET
M. Kawamura
1
, M. Yoshimura
1
, T. Katagiri
1
, T.
Mitsuyoshi
1
, H. Inokuchi
2
, T. Ishimori
3
, Y. Nakamoto
3
, T.
Mizowaki
1
, M. Hiraoka
2
1
Kyoto University- Graduate School of Medicine,
Radiation Oncology and Image-Applied Therapy, Kyoto,
Japan
2
Japanese Red Cross Wakayama Medical Center,
Radiation Oncology, Wakayama, Japan
3
Kyoto University- Graduate School of Medicine,
Diagnostic Imaging and Nuclear Medicine, Kyoto, Japan
Purpose or Objective
Positron emission tomography (PET) / computed
tomography (CT) using 18F-fluoromisonidazole (FMISO) has
been used as an imaging tool for tumor hypoxia. It has
been reported that several quantitative values in FMISO-
PET at 4-h postinjection were reproducible. However, it is
controversial whether they are reproducible when
scanning is performed in earlier time, e.g. 2-h
postinjection. If quantitative values at 2-h postinjection
are equivalent with those at 4-h postinjection, the total
examination time in FMISO-PET can be shortened. The
purpose of this study was to investigate the difference of
quantitative values in FMISO-PET at 2-h and 4-h
postinjection in patients with head and neck cancer.
Material and Methods
A total of 10 patients with untreated locally-advanced
head and neck cancer who underwent FMISO-PET/CT scan
from August 2015 to October 2016 in our institute were
analyzed. Image acquisition was performed twice, 2-h and
4-h after administration of FMISO using a combined
PET/CT scanner (Discovery IQ, GE Healthcare). After
taking a region of interest in a primary tumor, the
maximum standardized uptake value (SUVmax), SUVmean,
SUVpeak, tumor-to-blood ratio (TBR), tumor-to-muscle
ratio (TMR), metabolic tumor volume (MTV) and total
lesion hypoxia (TLH) were measured. We evaluated the
Spearman's rank correlation coefficients of these
quantitative values, and also calculated the percent
difference defined as difference between the two values
divided by average of two values.
Results
SUVmax (mean±SD) at 2-h and at 4-h were 2.4±0.8, and
2.6±1.0, respectively, in this population. The Spearman's
rank correlation coefficients of SUVmax, SUVmean,
SUVpeak, TBR, TMR, MTV, and TLH were 0.97, 0.97, 0.97,
0.93, 0.93, 0.95, and 0.95, respectively. The percent
differences (mean±SD) of these values were 8.3±5.6%,
6.8±6.3%, 4.1±5.1%, 16.8±12.5%, 17.1±9.1%, 42.7±52.7%,
and 41.7±58.1%, respectively. Quantitative values were
highly correlated between the two scans; however, there
were two cases in which %differences of MTV and TLH
exceeded 50%, i.e. 62.1% and 166.7% in MTV and 57.1% and
180.0% in
TLH.
Conclusion
Our preliminary data demonstrate that quantitative values
at 2-h and 4-h were highly reproducible. In a few patients,
volumetric parameters had moderate percent difference,
so it needs careful evaluation to measure hypoxic tumor
volume at 2-h after administration of FMISO.
EP-1069 Survival-weight health profile in
nasopharyngeal cancer patients
C.H. Lai
1
, W.C. Chen
1
, M.F. Chen
1
1
Chang-Gung Memorial Hospital- Chiayi branch,
Radiation Oncology, Chiayi Conuty, Taiwan
Purpose or Objective
This
study was designed to estimate the life expectancy (LE),
quality-adjusted life expectancy (QALE) and survival-
weight psychometric scores (SWPS) in nasopharyngeal
cancer (NPC) patients.
Material and Methods
A sample of 875 non-metastatic NPC patients diagnosed
between January 1, 2009 and June 30, 2013 was collected
from the cancer registry database in four branch hospitals
of our hospital system for estimation of lifetime survival
function. All 875 patients were followed up until death or
censored on December 31, 2015. To obtain the utility and
psychometric score for estimation of LE, QALE and SWPS,
eighty-seven patients were measured with the Taiwanese
version of the EuroQol instrument (EQ-5D) and the Taiwan
Chinese versions of the European Organization for
Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire (QLQ)-C30 and QLQ-H&N35 between